Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000674414 | SCV000799747 | likely pathogenic | Cholestanol storage disease | 2018-05-03 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000674414 | SCV001381317 | pathogenic | Cholestanol storage disease | 2024-05-07 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Leu394Alafs*18) in the CYP27A1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CYP27A1 are known to be pathogenic (PMID: 9392430, 10775536, 26937392). This variant is present in population databases (no rsID available, gnomAD 0.0009%). This premature translational stop signal has been observed in individual(s) with cerebrotendinous xanthomatosis (PMID: 11181744). This variant is also known as Ex6Δ2bp. ClinVar contains an entry for this variant (Variation ID: 558186). For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV000674414 | SCV004192665 | pathogenic | Cholestanol storage disease | 2023-09-26 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000674414 | SCV005647750 | likely pathogenic | Cholestanol storage disease | 2024-03-02 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV000674414 | SCV002078801 | pathogenic | Cholestanol storage disease | 2020-06-30 | no assertion criteria provided | clinical testing |